Watanabe Y, Kobayashi R, Ishikawa T, Hidaka H
Department of Pharmacology, Nagoya University School of Medicine, Japan.
Arch Biochem Biophys. 1992 Feb 1;292(2):563-9. doi: 10.1016/0003-9861(92)90031-q.
W-66 (N-(2-aminoethyl)-N-[2-(4-chlorocinnamylamino) ethyl]-5-isoquinolinesulfonamide), a newly synthesized isoquinolinesulfonamide, was shown to have a potent vasodilatory action and calmodulin (CaM)-antagonizing action. Using the W-66 affinity chromatographic technique, we purified two Ca(2+)-binding proteins from the EGTA-soluble fraction of bovine aorta. One was CaM and the other was an acidic protein with a molecular mass of 11 kDa. It was tentatively named "calvasculin." Calvasculin was a dimeric protein. Equilibrium dialysis showed that 1 mol of calvasculin (dimer) bound to 1.98 +/- 0.30 mol of Ca2+ in the presence of 10(-3) M Ca2+. Calvasculin failed to activate Ca2+/CaM-dependent enzymes such as myosin light chain kinase, Ca2+/CaM-dependent phosphodiesterase, or Ca2+/CaM-dependent protein kinase II and to inhibit the CaM stimulation of these enzymes. The partial amino acid sequence of calvasculin revealed a high homology to the predicted protein derived from mRNA, named pEL-98, 18A2, 42A, or p9Ka. We also examined the physicochemical and biochemical properties of calvasculin. Using the antibody specific for calvasculin, we obtained evidence that calvasculin is present in abundance in bovine aorta but not in brain, lung, heart, or testis.
W - 66(N -(2 - 氨乙基)- N - [2 -(4 - 氯肉桂氨基)乙基]- 5 - 异喹啉磺酰胺),一种新合成的异喹啉磺酰胺,已被证明具有强大的血管舒张作用和钙调蛋白(CaM)拮抗作用。利用W - 66亲和色谱技术,我们从牛主动脉的EGTA可溶部分纯化出两种Ca(2 +)结合蛋白。一种是CaM,另一种是分子量为11 kDa的酸性蛋白。它被暂时命名为“血管钙蛋白”。血管钙蛋白是一种二聚体蛋白。平衡透析表明,在10(-3) M Ca2 +存在的情况下,1摩尔血管钙蛋白(二聚体)与1.98±0.30摩尔Ca2 +结合。血管钙蛋白未能激活Ca2 +/CaM依赖性酶,如肌球蛋白轻链激酶、Ca2 +/CaM依赖性磷酸二酯酶或Ca2 +/CaM依赖性蛋白激酶II,也未能抑制这些酶的CaM刺激作用。血管钙蛋白的部分氨基酸序列与源自mRNA的预测蛋白pEL - 98、18A2、42A或p9Ka具有高度同源性。我们还研究了血管钙蛋白的物理化学和生化特性。使用针对血管钙蛋白的特异性抗体,我们获得的证据表明,血管钙蛋白在牛主动脉中大量存在,但在脑、肺、心脏或睾丸中不存在。